(Q47282777)

13 January 2018

title

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? (English)

1 reference

13 January 2018

1 reference

4

1 reference

13 January 2018

author name string

Andreyev HJ

series ordinal

1

1 reference

13 January 2018

Norman AR

series ordinal

2

1 reference

13 January 2018

Oates J

series ordinal

3

1 reference

13 January 2018

publication date

1 March 1998

1 reference

13 January 2018

European Journal of Cancer

published in

1 reference

13 January 2018

volume

34

1 reference

13 January 2018

issue

4

1 reference

13 January 2018

page(s)

503-509

1 reference

13 January 2018

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Prognostic factors influencing survival of patients with advanced colorectal cancer: hepatic-artery infusion versus systemic intravenous chemotherapy for liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Nutrition support in patients with cancer: what do the data really show?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Total parenteral nutrition and cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

Total parenteral nutrition in the cancer patient

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910090-9

7 January 2021

10.1016/S0959-8049(97)10090-9

Identifiers

DOI

1 reference

13 January 2018

PubMed ID

9713300

1 reference

13 January 2018